SCORPIO-PEP Phase 3: Ensitrelvir First Oral Antiviral to Prevent COVID-19 Post-Exposure
SCORPIO-PEP Phase 3: Ensitrelvir First Oral Antiviral to Prevent COVID-19 Post-Exposure Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) presented late-breaking scientific…
Merck’s Phase 3 Trials Show DOR/ISL Maintains HIV-1 Suppression at 48 Weeks
Merck’s Phase 3 Trials Show DOR/ISL Maintains HIV-1 Suppression at 48 Weeks Merck, known as MSD outside of the United States and Canada, has announced promising results from two pivotal…
Gilead Unveils New HIV Treatment Data at CROI 2025
Gilead Unveils New HIV Treatment Data at CROI 2025 Gilead Sciences, Inc. has unveiled a significant array of late-breaking data and multiple oral presentations from its groundbreaking HIV treatment portfolio…
City of Hope’s Phase 1 Trial Featured at SSO Annual Meeting
City of Hope’s Phase 1 Trial Featured at SSO Annual Meeting City of Hope’s groundbreaking Phase 1 clinical trial has demonstrated promising results for patients suffering from colorectal and appendiceal…
LGM Pharma Invests $6M to Expand U.S. Drug Manufacturing
LGM Pharma Invests $6 Million to Expand U.S. Drug Manufacturing Capabilities LGM Pharma, a leading provider of tailored active pharmaceutical ingredient (API) and contract development and manufacturing organization (CDMO) services,…
Shift Bioscience Strengthens Team for Rejuvenation Therapeutics
Shift Bioscience Strengthens Leadership Team to Accelerate Rejuvenation Therapeutics Development Shift Bioscience, a pioneering biotechnology company utilizing an AI-powered virtual cell platform to combat age-related diseases, has announced the strategic…
PharmaCord & Mercalis Merge to Advance Biopharma Solutions
PharmaCord & Mercalis Merge to Advance Biopharma Solutions PharmaCord LLC (“PharmaCord”), a leading provider of patient services for the biopharmaceutical industry, and Mercalis, an integrated life sciences commercialization partner, have…
InTandem Capital Invests in Clinilabs
InTandem Capital Invests in Clinilabs InTandem Capital Partners (“InTandem Capital” or the “Firm”), a private equity firm specializing in healthcare services, has officially announced its strategic partnership with Clinilabs (the…
Generative AI Reshapes the Disparate Health Technology Assessment Landscape
Generative AI Revolutionizes Health Technology Assessment Landscape: Trinity Life Sciences Enhances HTA Vision Trinity Life Sciences, a leading provider of strategy, insights, and analytics for the life sciences industry, has…
Seismic Therapeutic Starts Phase 1 Trial of S-1117 for Antibody-Mediated Diseases
Seismic Therapeutic Starts Phase 1 Trial of S-1117 for Antibody-Mediated Diseases Seismic Therapeutic, Inc., a machine learning-driven immunology company, has announced a significant milestone in its journey toward developing transformative…
Cellino and Matricelf Partner to Advance Personalized Spinal Cord Injury Treatments
Cellino and Matricelf Partner to Scale Personalized Spinal Cord Injury Treatments Cellino and Matricelf (TASE: MTLF) announced today a groundbreaking global collaboration aimed at accelerating the biomanufacturing of personalized spinal…
Nosis Biosciences Partners with Daiichi Sankyo on RNA Medicines
Nosis Biosciences and Daiichi Sankyo Partner to Advance RNA Medicines Nosis Biosciences, an AI-driven biotechnology company specializing in RNA therapeutics for challenging cell types, has announced a Research Collaboration and…